Prognostic and Predictive Biomarkers in Stage III Melanoma: Current Insights and Clinical Implications
Melanoma is one of the most aggressive skin cancers. The 5-year survival rate of stage III melanoma patients ranges from 93% (IIIA) to 32% (IIID) with a high risk of recurrence after complete surgery. The introduction of target and immune therapies has dramatically improved the overall survival, but...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-04-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/9/4561 |
| _version_ | 1797536182162161664 |
|---|---|
| author | Luca Tonella Valentina Pala Renata Ponti Marco Rubatto Giuseppe Gallo Luca Mastorino Gianluca Avallone Martina Merli Andrea Agostini Paolo Fava Luca Bertero Rebecca Senetta Simona Osella-Abate Simone Ribero Maria Teresa Fierro Pietro Quaglino |
| author_facet | Luca Tonella Valentina Pala Renata Ponti Marco Rubatto Giuseppe Gallo Luca Mastorino Gianluca Avallone Martina Merli Andrea Agostini Paolo Fava Luca Bertero Rebecca Senetta Simona Osella-Abate Simone Ribero Maria Teresa Fierro Pietro Quaglino |
| author_sort | Luca Tonella |
| collection | DOAJ |
| description | Melanoma is one of the most aggressive skin cancers. The 5-year survival rate of stage III melanoma patients ranges from 93% (IIIA) to 32% (IIID) with a high risk of recurrence after complete surgery. The introduction of target and immune therapies has dramatically improved the overall survival, but the identification of patients with a high risk of relapse who will benefit from adjuvant therapy and the determination of the best treatment choice remain crucial. Currently, patient prognosis is based on clinico-pathological features, highlighting the urgent need of predictive and prognostic markers to improve patient management. In recent years, many groups have focused their attention on identifying molecular biomarkers with prognostic and predictive potential. In this review, we examined the main candidate biomarkers reported in the literature. |
| first_indexed | 2024-03-10T11:56:00Z |
| format | Article |
| id | doaj.art-7736db38898347499008bc472a934120 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T11:56:00Z |
| publishDate | 2021-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-7736db38898347499008bc472a9341202023-11-21T17:19:55ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-04-01229456110.3390/ijms22094561Prognostic and Predictive Biomarkers in Stage III Melanoma: Current Insights and Clinical ImplicationsLuca Tonella0Valentina Pala1Renata Ponti2Marco Rubatto3Giuseppe Gallo4Luca Mastorino5Gianluca Avallone6Martina Merli7Andrea Agostini8Paolo Fava9Luca Bertero10Rebecca Senetta11Simona Osella-Abate12Simone Ribero13Maria Teresa Fierro14Pietro Quaglino15Department of Medical Sciences, Dermatologic Clinic, University of Turin, 10126 Turin, ItalyDepartment of Medical Sciences, Dermatologic Clinic, University of Turin, 10126 Turin, ItalyDepartment of Medical Sciences, Dermatologic Clinic, University of Turin, 10126 Turin, ItalyDepartment of Medical Sciences, Dermatologic Clinic, University of Turin, 10126 Turin, ItalyDepartment of Medical Sciences, Dermatologic Clinic, University of Turin, 10126 Turin, ItalyDepartment of Medical Sciences, Dermatologic Clinic, University of Turin, 10126 Turin, ItalyDepartment of Medical Sciences, Dermatologic Clinic, University of Turin, 10126 Turin, ItalyDepartment of Medical Sciences, Dermatologic Clinic, University of Turin, 10126 Turin, ItalyDepartment of Medical Sciences, Dermatologic Clinic, University of Turin, 10126 Turin, ItalyDepartment of Medical Sciences, Dermatologic Clinic, University of Turin, 10126 Turin, ItalyDepartment of Oncology, Pathology Unit, University of Turin, 10126 Turin, ItalyDepartment of Oncology, Pathology Unit, University of Turin, 10126 Turin, ItalyDepartment of Oncology, Pathology Unit, University of Turin, 10126 Turin, ItalyDepartment of Medical Sciences, Dermatologic Clinic, University of Turin, 10126 Turin, ItalyDepartment of Medical Sciences, Dermatologic Clinic, University of Turin, 10126 Turin, ItalyDepartment of Medical Sciences, Dermatologic Clinic, University of Turin, 10126 Turin, ItalyMelanoma is one of the most aggressive skin cancers. The 5-year survival rate of stage III melanoma patients ranges from 93% (IIIA) to 32% (IIID) with a high risk of recurrence after complete surgery. The introduction of target and immune therapies has dramatically improved the overall survival, but the identification of patients with a high risk of relapse who will benefit from adjuvant therapy and the determination of the best treatment choice remain crucial. Currently, patient prognosis is based on clinico-pathological features, highlighting the urgent need of predictive and prognostic markers to improve patient management. In recent years, many groups have focused their attention on identifying molecular biomarkers with prognostic and predictive potential. In this review, we examined the main candidate biomarkers reported in the literature.https://www.mdpi.com/1422-0067/22/9/4561melanomastage IIIbiomarkersadjuvant therapy |
| spellingShingle | Luca Tonella Valentina Pala Renata Ponti Marco Rubatto Giuseppe Gallo Luca Mastorino Gianluca Avallone Martina Merli Andrea Agostini Paolo Fava Luca Bertero Rebecca Senetta Simona Osella-Abate Simone Ribero Maria Teresa Fierro Pietro Quaglino Prognostic and Predictive Biomarkers in Stage III Melanoma: Current Insights and Clinical Implications International Journal of Molecular Sciences melanoma stage III biomarkers adjuvant therapy |
| title | Prognostic and Predictive Biomarkers in Stage III Melanoma: Current Insights and Clinical Implications |
| title_full | Prognostic and Predictive Biomarkers in Stage III Melanoma: Current Insights and Clinical Implications |
| title_fullStr | Prognostic and Predictive Biomarkers in Stage III Melanoma: Current Insights and Clinical Implications |
| title_full_unstemmed | Prognostic and Predictive Biomarkers in Stage III Melanoma: Current Insights and Clinical Implications |
| title_short | Prognostic and Predictive Biomarkers in Stage III Melanoma: Current Insights and Clinical Implications |
| title_sort | prognostic and predictive biomarkers in stage iii melanoma current insights and clinical implications |
| topic | melanoma stage III biomarkers adjuvant therapy |
| url | https://www.mdpi.com/1422-0067/22/9/4561 |
| work_keys_str_mv | AT lucatonella prognosticandpredictivebiomarkersinstageiiimelanomacurrentinsightsandclinicalimplications AT valentinapala prognosticandpredictivebiomarkersinstageiiimelanomacurrentinsightsandclinicalimplications AT renataponti prognosticandpredictivebiomarkersinstageiiimelanomacurrentinsightsandclinicalimplications AT marcorubatto prognosticandpredictivebiomarkersinstageiiimelanomacurrentinsightsandclinicalimplications AT giuseppegallo prognosticandpredictivebiomarkersinstageiiimelanomacurrentinsightsandclinicalimplications AT lucamastorino prognosticandpredictivebiomarkersinstageiiimelanomacurrentinsightsandclinicalimplications AT gianlucaavallone prognosticandpredictivebiomarkersinstageiiimelanomacurrentinsightsandclinicalimplications AT martinamerli prognosticandpredictivebiomarkersinstageiiimelanomacurrentinsightsandclinicalimplications AT andreaagostini prognosticandpredictivebiomarkersinstageiiimelanomacurrentinsightsandclinicalimplications AT paolofava prognosticandpredictivebiomarkersinstageiiimelanomacurrentinsightsandclinicalimplications AT lucabertero prognosticandpredictivebiomarkersinstageiiimelanomacurrentinsightsandclinicalimplications AT rebeccasenetta prognosticandpredictivebiomarkersinstageiiimelanomacurrentinsightsandclinicalimplications AT simonaosellaabate prognosticandpredictivebiomarkersinstageiiimelanomacurrentinsightsandclinicalimplications AT simoneribero prognosticandpredictivebiomarkersinstageiiimelanomacurrentinsightsandclinicalimplications AT mariateresafierro prognosticandpredictivebiomarkersinstageiiimelanomacurrentinsightsandclinicalimplications AT pietroquaglino prognosticandpredictivebiomarkersinstageiiimelanomacurrentinsightsandclinicalimplications |